## MEDP: Medpace Holdings, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 6.6% in lower entry zone (4.0-10.0%), top quartile (88th pct) cross-sectional ranking. Short-term MRS_5 (4.3%) confirms momentum alignment. Strong momentum (+5.7% 5-day acceleration). Outperforming sector by 5.0%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($577.93)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 9, 2026**
- Source: Business Wire | 20260105T210958 | Neutral | Relevance: 100%
- Medpace Holdings, Inc. (Nasdaq: MEDP) announced it will release its fourth quarter and fiscal year 2025 financial results after market close on Monday, February 9, 2026. The company will host a conference call on Tuesday, February 10, 2026, at 9:00 a.m. ET to discuss these results, with registration required for participation. Interested parties can access the webcast and a supplemental slide presentation via the "Investors" section of Medpace's website.

**2. Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 9, 2026**
- Source: Bluefield Daily Telegraph | 20260105T210958 | Neutral | Relevance: 100%
- Medpace Holdings, Inc. announced it will report its fourth quarter and fiscal year 2025 financial results on February 9, 2026, after market close. The company will host a conference call on February 10, 2026, at 9:00 a.m. ET to discuss these results, with details provided for participation and webcast access. Medpace is a scientifically-driven global clinical research organization providing clinical development services.

**3. Medpace Holdings: Quiet Climb Or Topping Out? What The Numbers Really Say About MEDP**
- Source: AD HOC NEWS | 20260105T014553 | Bullish | Relevance: 100%
- Medpace Holdings (MEDP) has seen modest declines recently but remains near its 52-week high after a strong multi-month rally, prompting investors to question if it's poised for further gains or facing consolidation. Wall Street's outlook is broadly positive, with most analysts holding "Buy" or "Overweight" ratings, albeit with a focus on Mepace's continued execution and industry trends. The company's future hinges on sustained contract wins, disciplined margin management, and favorable biopharma funding conditions.

**4. Medpace Holdings: Can This Quiet Compounder Keep Beating Wall Streetâ€™s Playbook?**
- Source: AD HOC NEWS | 20260104T174631 | Bullish | Relevance: 100%
- Medpace Holdings, a clinical research organization, has shown strong stock performance, trading near record highs despite wider market volatility. The company's success is attributed to disciplined execution in managing clinical trials, particularly in complex therapeutic areas. Wall Street analysts largely maintain a "Buy" consensus, with price targets suggesting further modest upside, indicating continued confidence in Medpace's growth trajectory and operational excellence.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $525 | $485 | +8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 4 ($0.23M) |
| Sells | 29 ($216.47M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 36.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 8.4% (-4.4%)
- Vanguard Group Inc: 8.1% (-4.5%)
- AQR Capital Manageme: 3.6% (+65.1%)
- Wasatch Advisors LP: 3.3% (-2.1%)
- State Street Corpora: 2.4% (-4.8%)

### Key Risks

1. Heavy insider selling: $216M sold (29 transactions in 90 days).
2. Valuation stretched: PEG 3.6x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Momentum building: MRS_20 improving +5.7% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.56 signals overvaluation risk, limited margin of safety. Forward P/E 36.9x stretched relative to 9% growth. Quality metrics strong (ROE 74%, ROA 16%, margin 18%). Analyst sentiment positive (1 raises, avg +8%). Insider selling cluster ($216.5M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $17.2B |
| Beta | 1.44 |
| 52W Range | $250.05 - $626.25 |
| Short Interest | 6.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.56 |
| Forward P/E | 36.9 |
| Current P/E | 40.3 |
| YoY Growth | 9.2% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from 0.9% to 6.6% (+5.7% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 88th percentile. MRS_5 at 4.3% confirms short-term momentum alignment. AM_20 at 7.5% shows strong absolute momentum above own 20MA. Outperforming sector by 5.0pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (4.13), confirming momentum. OFD pattern: +FTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 6.64% (CS: 88) | Strong |
| RSI_14 | 68.5 | Neutral |
| MACD Histogram | 4.13 | Bullish |
| vs SMA20 | 1.075x | Above |
| vs SMA50 | 1.049x | Above |
| vs SMA200 | 1.402x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $608.89
- **Stop Loss:** $577.93 (5.1% risk)
- **Target:** $655.33 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 42
- **Position Value:** $25,573.38
- **Portfolio %:** 25.57%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-09 (Est: $4.21)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.57 | $3.86 | +8.1% |
| 2025Q2 | $3.00 | $3.10 | +3.5% |
| 2025Q1 | $3.07 | $3.67 | +19.6% |
| 2024Q4 | $3.12 | $3.68 | +18.1% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_20*